Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TK2 | O00142 | 6/20 | 0.46 |
| ▸ | TK1 | P04183 | 6/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080424 | 0.84 | CYP19A1 (0.43) | NPC1RAB9ACYP19A1SRCMEN1 | |
| SCHEMBL16631662 | 0.81 | HPGD (0.56) | HPGDMAPK1TK2TK1 | |
| SCHEMBL16631675 | 0.80 | MAPK1 (0.48) | HPGDMAPK1TK2TK1 | |
| SCHEMBL16631677 | 0.76 | MAPK1 (0.44) | HPGDMAPK1TK2TK1 | |
| SCHEMBL18081935 | 0.75 | MAPK1 (0.43) | HPGDMAPK1TK2TK1 | |
| SCHEMBL16631457 | 0.74 | TK2 (0.44) | TK2TK1 | |
| SCHEMBL16631913 | 0.72 | CYP19A1 (0.52) | NPC1RAB9ACYP19A1MEN1KMT2A | |
| SCHEMBL18081921 | 0.72 | HPGD (0.69) | HPGDMAPK1TK1CYP19A1 | |
| SCHEMBL18080400 | 0.71 | CYP19A1 (0.50) | NPC1RAB9ACYP19A1SRCMEN1 | |
| SCHEMBL16631672 | 0.70 | MAPK1 (0.47) | HPGDMAPK1TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | HPGD 3931/4885NPC1 1636/4885RAB9A 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.